EHA 2018 | Response to MM therapy can vary based on a variety of factors

Shaji Kumar

The response of patients with multiple myeloma (MM) to therapy is always variable. Speaking from the 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden, Shaji Kumar, MD, of the Mayo Clinic, Rochester, MN, explains why an immediate and strong response to therapy isn’t always the best outcome to hope for, and mentions the factors that can have an impact on the efficacy of some drugs, from the biology of the disease to patient fitness.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter